Your institution may have access to this item. Find your institution then sign in to continue.
Title
Libtayo plus Platinum-Based Chemotherapy Now FDA Approved for NSCLC without Genomic Aberrations.
Abstract
The article informs the combination of platinum-based chemotherapy and the PD-1 inhibitor cemiplimab-rwlc has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with advanced NSCLC who do not have EGFR, ALK, or ROS1 abnormalities.